{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:58:38Z","timestamp":1793818718337,"version":"4.6.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The lack of target therapies is accountable for the higher mortality of various types of cancer. To address this issue, we selected a target mutated Kirsten rat sarcoma virus oncogene homologue, which plays a significant role in various cancers. Our study aims to identify selective biomarkers and develop diagnostic and therapeutic strategies for KRAS-associated genes using artificial intelligence. Initially, Genomic data, cancer epidemiology, proteomics network interactions, and omics enrichment were analyzed. Structured E-pharmacophore model aided in capturing the binding cavity using eraser algorithms and fabricating a new selective lead compound for the KRSA. The selective molecule was abridged inside the binding cavity and stability was validated through 100 ns molecular dynamics simulations. Epidemiological-neural network studies indicated KRAS mutations leads 40 types of cancer, exclusively pancreatic and colorectal cancers, with diploid and missense mutations as primary factors. Pathway analysis highlighted the involvement of the MAPK and RAS signaling pathways in cancer development and proteomics analysis identified RALGDS as a key protein. Protein-based pharmacophore analysis mapped the biologically active features such as donor, acceptor and aromatic ring with the designed ligands. The results of interaction interpretation illustrate that the amino acid Tyr566 formed an H-bond interaction with the amine group of the octyl ring system and 20 amino acids crafted to properly orient the molecule to fit inside the polar cavity of KRAS protein. The MMGBSA score of \u2212\u00a053.33\u00a0kcal\/mol conformed to the well-configured binding with KRSA and realistic model simulation exposed the \u03c0\u2013\u03c0, \u03c0\u2013cationic and hydrophobic interactions stabilised the molecule inside the KRSA protein throughout 100\u00a0ns simulation. The study demonstrates the vitality of AI and network pharmacology to identify potential-target biomarkers for KRAS-associated genes, paving the way for improved cancer diagnostics and therapeutics.<\/jats:p>","DOI":"10.1038\/s41598-025-91568-x","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T02:21:16Z","timestamp":1743301276000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Network pharmacology and AI in cancer research uncovering biomarkers and therapeutic targets for RALGDS mutations"],"prefix":"10.1038","volume":"15","author":[{"given":"S. Mohammed","family":"Zaidh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hariharan Thirumalai","family":"Vengateswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Habeeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran Balasaheb","family":"Aher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girija Balasaheb","family":"Bhavar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Irfan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K N V Chenchu","family":"Lakshmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"key":"91568_CR1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2394009","author":"F Attieh","year":"2024","unstructured":"Attieh, F. & Kourie, H. R. Breaking barriers: The latest insights into KRAS G12C inhibitors. Future Oncol. https:\/\/doi.org\/10.1080\/14796694.2024.2394009 (2024).","journal-title":"Future Oncol."},{"key":"91568_CR2","first-page":"887","volume":"18","author":"HA Hou","year":"2020","unstructured":"Hou, H. A. & Tien, H. F. Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies. J. Biomed. Sci. 27, 81 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"91568_CR3","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/d41573-019-00195-5","volume":"18","author":"A Mullard","year":"2019","unstructured":"Mullard, A. Cracking KRAS. Nat. Rev. Drug Discov. 18, 887\u2013891 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"91568_CR4","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1038\/s41375-019-0444-6","volume":"33","author":"E Vendramini","year":"2019","unstructured":"Vendramini, E. et al. KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. Leukemia 33, 2111\u20132115 (2019).","journal-title":"Leukemia"},{"key":"91568_CR5","doi-asserted-by":"publisher","first-page":"107886","DOI":"10.1016\/j.lungcan.2024.107886","volume":"194","author":"Y Oya","year":"2024","unstructured":"Oya, Y., Imaizumi, K. & Mitsudomi, T. The next-generation KRAS inhibitors\u2026 What comes after Sotorasib and adagrasib? Lung Cancer 194, 107886 (2024).","journal-title":"Lung Cancer"},{"key":"91568_CR6","doi-asserted-by":"publisher","first-page":"LBA8509","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8509","volume":"42","author":"TSK Mok","year":"2024","unstructured":"Mok, T. S. K. et al. KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced\/metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation. J. Clin. Oncol. 42, LBA8509\u2013LBA8509 (2024).","journal-title":"J. Clin. Oncol."},{"key":"91568_CR7","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41568-020-0290-x","volume":"20","author":"F Mart\u00ednez-Jim\u00e9nez","year":"2020","unstructured":"Mart\u00ednez-Jim\u00e9nez, F. et al. A compendium of mutational cancer driver genes. Nat. Rev. Cancer 20, 555\u2013572 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"91568_CR8","doi-asserted-by":"publisher","first-page":"100058","DOI":"10.1016\/j.apjo.2024.100058","volume":"13","author":"M Zhou","year":"2024","unstructured":"Zhou, M. et al. Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management. Asia-Pacific J. Ophthalmol. 13, 100058 (2024).","journal-title":"Asia-Pacific J. Ophthalmol."},{"key":"91568_CR9","doi-asserted-by":"publisher","first-page":"e37362","DOI":"10.1097\/MD.0000000000037362","volume":"103","author":"Y Shi","year":"2024","unstructured":"Shi, Y. et al. Comprehensive pan-cancer analysis of 33 human cancers reveals immunotherapeutic value of focal adhesion tyrosine kinase. Medicine 103, e37362 (2024).","journal-title":"Medicine"},{"key":"91568_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41420-024-01803-z","volume":"10","author":"X Yu","year":"2024","unstructured":"Yu, X. et al. Cancer epigenetics: From laboratory studies and clinical trials to precision medicine. Cell. Death Discov. 10, 28 (2024).","journal-title":"Cell. Death Discov"},{"key":"91568_CR11","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.3748\/wjg.v27.i27.4298","volume":"27","author":"JX Hu","year":"2021","unstructured":"Hu, J. X. et al. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World J. Gastroenterol. 27, 4298\u20134321 (2021).","journal-title":"World J. Gastroenterol."},{"key":"91568_CR12","doi-asserted-by":"publisher","first-page":"66087","DOI":"10.18632\/oncotarget.19798","volume":"8","author":"JD Zhou","year":"2017","unstructured":"Zhou, J. D. et al. KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia. Oncotarget 8, 66087\u201366097 (2017).","journal-title":"Oncotarget"},{"key":"91568_CR13","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/leu.2017.303","volume":"32","author":"IS Jerchel","year":"2018","unstructured":"Jerchel, I. S. et al. RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia. Leukemia 32, 931\u2013940 (2018).","journal-title":"Leukemia"},{"key":"91568_CR14","doi-asserted-by":"publisher","first-page":"6630","DOI":"10.18632\/oncotarget.23553","volume":"9","author":"M del Re","year":"2018","unstructured":"del Re, M. et al. Implications of KRAS mutations in acquired resistance to treatment in NSCLC. Oncotarget 9, 6630\u20136643 (2018).","journal-title":"Oncotarget"},{"key":"91568_CR15","doi-asserted-by":"crossref","unstructured":"Reita, D. et al. Direct targeting KRAS mutation in non-small cell lung cancer: Focus on resistance. Cancers (Basel) 14 (2022).","DOI":"10.3390\/cancers14051321"},{"key":"91568_CR16","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41588-019-0572-y","volume":"52","author":"F Dietlein","year":"2020","unstructured":"Dietlein, F. Identification of cancer driver genes based on nucleotide context. Nat. Genet. 52, 208\u2013218 (2020).","journal-title":"Nat. Genet."},{"key":"91568_CR17","unstructured":"A compendium of mutational cancer driver genes. Nat. Rev. Cancer. https:\/\/www.nature.com\/articles\/s41568-020-0290-x"},{"key":"91568_CR18","doi-asserted-by":"crossref","unstructured":"Hussain, A. & Brooks, C. L. III Guiding discovery of protein sequence-structure-function modeling. Bioinformatics 40 (2024).","DOI":"10.1093\/bioinformatics\/btae002"},{"key":"91568_CR19","doi-asserted-by":"publisher","first-page":"18679","DOI":"10.1038\/s41598-024-65148-4","volume":"14","author":"R Kumar","year":"2024","unstructured":"Kumar, R. et al. Somatic mutational landscape across Indian breast cancer cases by whole exome sequencing. Sci. Rep. 14, 18679 (2024).","journal-title":"Sci. Rep."},{"key":"91568_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41421-021-00368-w","volume":"8","author":"Z Mao","year":"2022","unstructured":"Mao, Z. et al. KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge. Cell. Discov. 8, 5 (2022).","journal-title":"Cell. Discov"},{"key":"91568_CR21","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang, L., Guo, Z., Wang, F. & Fu, L. KRAS mutation: From undruggable to druggable in cancer. Signal. Transduct. Target. Ther. 6, 386 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"91568_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","volume":"21","author":"ZI Hu","year":"2024","unstructured":"Hu, Z. I. & O\u2019Reilly, E. M. Therapeutic developments in pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 21, 7\u201324 (2024).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"91568_CR23","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1021\/acsptsci.4c00075","volume":"7","author":"G Cornilescu","year":"2024","unstructured":"Cornilescu, G. et al. Natural product Graveoline modulates Kirsten rat sarcoma viral oncogene homologue (KRAS) membrane association: Insights from advanced spectroscopic studies. ACS Pharmacol. Transl Sci. 7, 1983\u20131995 (2024).","journal-title":"ACS Pharmacol. Transl Sci."},{"key":"91568_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","volume":"170","author":"DK Simanshu","year":"2017","unstructured":"Simanshu, D. K., Nissley, D. V. & McCormick, F. RAS proteins and their regulators in human disease. Cell 170, 17\u201333 (2017).","journal-title":"Cell"},{"key":"91568_CR25","doi-asserted-by":"crossref","unstructured":"Nourbakhsh, M., Degn, K., Saksager, A., Tiberti, M. & Papaleo, E. Prediction of cancer driver genes and mutations: The potential of integrative computational frameworks. Brief. Bioinform. 25 (2024).","DOI":"10.1093\/bib\/bbad519"},{"key":"91568_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-022-00994-0","volume":"7","author":"Y You","year":"2022","unstructured":"You, Y. et al. Artificial intelligence in cancer target identification and drug discovery. Signal. Transduct. Target. Ther. 7, 156 (2022).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"91568_CR27","doi-asserted-by":"publisher","first-page":"108118","DOI":"10.1016\/j.jsb.2024.108118","volume":"216","author":"S Akbarzadeh","year":"2024","unstructured":"Akbarzadeh, S., Co\u015fkun, \u00d6. & G\u00fcn\u00e7er, B. Studying protein\u2013protein interactions: Latest and most popular approaches. J. Struct. Biol. 216, 108118 (2024).","journal-title":"J. Struct. Biol."},{"key":"91568_CR28","doi-asserted-by":"crossref","unstructured":"Pepe, G. et al. Artificial intelligence methods enhance the discovery of RNA interactions. Front. Mol. Biosci. 9 (2022).","DOI":"10.3389\/fmolb.2022.1000205"},{"key":"91568_CR29","doi-asserted-by":"publisher","first-page":"355","DOI":"10.5483\/BMBRep.2017.50.7.062","volume":"50","author":"CW Han","year":"2017","unstructured":"Han, C. W., Jeong, M. S. & Jang, S. B. Structure, signaling and the drug discovery of the Ras oncogene protein. BMB Rep. 50, 355\u2013360 (2017).","journal-title":"BMB Rep."},{"key":"91568_CR30","doi-asserted-by":"publisher","first-page":"6450","DOI":"10.1021\/acs.jcim.4c01193","volume":"64","author":"JA Weller","year":"2024","unstructured":"Weller, J. A. & Rohs, R. Structure-based drug design with a deep hierarchical generative model. J. Chem. Inf. Model. 64, 6450\u20136463 (2024).","journal-title":"J. Chem. Inf. Model."},{"key":"91568_CR31","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1038\/s41388-023-02672-z","volume":"42","author":"A Garc\u00eda-Espa\u00f1a","year":"2023","unstructured":"Garc\u00eda-Espa\u00f1a, A. & Philips, M. R. Origin and evolution of RAS membrane targeting. Oncogene 42, 1741\u20131750 (2023).","journal-title":"Oncogene"},{"key":"91568_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41698-022-00334-z","volume":"6","author":"JK Lee","year":"2022","unstructured":"Lee, J. K. et al. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. NPJ Precis Oncol. 6, 91 (2022).","journal-title":"NPJ Precis Oncol."},{"key":"91568_CR33","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12859-017-1559-2","volume":"18","author":"A Fabregat","year":"2017","unstructured":"Fabregat, A. et al. Reactome pathway analysis: A high-performance in-memory approach. BMC Bioinform. 18, 142 (2017).","journal-title":"BMC Bioinform."},{"key":"91568_CR34","doi-asserted-by":"crossref","unstructured":"Chen, C. et al. Applications of multi-omics analysis in human diseases. MedComm (Beijing) 4 (2023).","DOI":"10.1002\/mco2.315"},{"key":"91568_CR35","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk, D. et al. The STRING database in 2023: Protein\u2013protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 51, D638\u2013D646 (2023).","journal-title":"Nucleic Acids Res."},{"key":"91568_CR36","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1038\/s41598-020-80900-2","volume":"11","author":"S Das","year":"2021","unstructured":"Das, S. & Chakrabarti, S. Classification and prediction of protein\u2013protein interaction interface using machine learning algorithm. Sci. Rep. 11, 1761 (2021).","journal-title":"Sci. Rep."},{"key":"91568_CR37","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1016\/j.csbj.2024.10.009","volume":"23","author":"L Daou","year":"2024","unstructured":"Daou, L. & Hanna, E. M. Predicting protein complexes in protein interaction networks using mapper and graph convolution networks. Comput. Struct. Biotechnol. J. 23, 3595\u20133609 (2024).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"91568_CR38","doi-asserted-by":"publisher","first-page":"100978","DOI":"10.1016\/j.drup.2023.100978","volume":"70","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. Multi-omics dissection of stage-specific artemisinin tolerance mechanisms in Kelch13-mutant plasmodium falciparum. Drug Resist. Updates 70, 100978 (2023).","journal-title":"Drug Resist. Updates"},{"key":"91568_CR39","doi-asserted-by":"publisher","first-page":"6184","DOI":"10.1038\/s41598-024-56286-w","volume":"14","author":"HT Zou","year":"2024","unstructured":"Zou, H. T., Ji, B. Y. & Xie, X. L. A multi-source molecular network representation model for protein\u2013protein interactions prediction. Sci. Rep. 14, 6184 (2024).","journal-title":"Sci. Rep."},{"key":"91568_CR40","doi-asserted-by":"publisher","unstructured":"Mohammed Zaidh, S. et al. Genes adaptability and NOL6 protein Inhibition studies of fabricated flavan-3-ols lead skeleton intended to treat breast carcinoma. Int. J. Biol. Macromol. 127661 https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.127661 (2023).","DOI":"10.1016\/j.ijbiomac.2023.127661"},{"key":"91568_CR41","doi-asserted-by":"publisher","unstructured":"Irfan, N. et al. Active and allosteric site binding MM-QM studies of methylidene tetracyclo derivative in PCSK9 protein intended to make a safe antilipidemic agent. J. Biomol. Struct. Dyn. 1\u201310 https:\/\/doi.org\/10.1080\/07391102.2023.2239928 (2023).","DOI":"10.1080\/07391102.2023.2239928"},{"key":"91568_CR42","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s12033-021-00358-z","volume":"63","author":"I Navabshan","year":"2021","unstructured":"Navabshan, I. et al. Computational lock and key and dynamic trajectory analysis of natural biophors against COVID-19 Spike protein to identify effective lead molecules. Mol. Biotechnol. 63, 898\u2013908 (2021).","journal-title":"Mol. Biotechnol."},{"key":"91568_CR43","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s12010-021-03763-x","volume":"194","author":"GN Ravi","year":"2022","unstructured":"Ravi, G. N., Navabshan, I., Unnikrishnan, S. & Ramalingam, K. In silico protein-protein interaction of pterois volitans venom with cancer inducers of Helicobacter pylori. Appl. Biochem. Biotechnol. 194, 354\u2013367 (2022).","journal-title":"Appl. Biochem. Biotechnol."},{"key":"91568_CR44","doi-asserted-by":"publisher","first-page":"9437","DOI":"10.1080\/07391102.2022.2146751","volume":"41","author":"N Irfan","year":"2023","unstructured":"Irfan, N., Balasubramaniyan, S., Ali, D. M. & Puratchikody, A. Bioisosteric replacements of tyrosine kinases inhibitors to make potent and safe chemotherapy against malignant cells. J. Biomol. Struct. Dyn. 41, 9437\u20139447 (2023).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"91568_CR45","doi-asserted-by":"publisher","unstructured":"Habeeb, M. et al. Development characterization and molecular simulation studies of metoclopramide HCl and tramadol HCl bilayer tablets. Res. J. Pharm. Technol. 529\u2013534. https:\/\/doi.org\/10.52711\/0974-360X.2022.00085 (2022).","DOI":"10.52711\/0974-360X.2022.00085"},{"key":"91568_CR46","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s00894-020-04464-8","volume":"26","author":"H Haghkhah","year":"2020","unstructured":"Haghkhah, H., Ghalami Choobar, B. & Amjad-Iranagh, S. Effect of salt concentration on properties of mixed carbonate-based electrolyte for Li-ion batteries: A molecular dynamics simulation study. J. Mol. Model. 26, 220 (2020).","journal-title":"J. Mol. Model."},{"key":"91568_CR47","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41597-022-01527-8","volume":"9","author":"KP Gregory","year":"2022","unstructured":"Gregory, K. P., Elliott, G. R., Wanless, E. J., Webber, G. B. & Page, A. J. A quantum chemical molecular dynamics repository of solvated ions. Sci. Data 9, 430 (2022).","journal-title":"Sci. Data"},{"key":"91568_CR48","unstructured":"RMSD\/RMSF Analysis | BioChemCoRe (2018). https:\/\/ctlee.github.io\/BioChemCoRe-2018\/rmsd-rmsf\/"},{"key":"91568_CR49","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3389\/fchem.2020.00726","volume":"8","author":"F Wu","year":"2020","unstructured":"Wu, F. et al. Computational approaches in preclinical studies on drug discovery and development. Front. Chem. 8, 726 (2020).","journal-title":"Front. Chem."},{"key":"91568_CR50","doi-asserted-by":"publisher","first-page":"100422","DOI":"10.1016\/j.phyplu.2023.100422","volume":"3","author":"CS Kumar","year":"2023","unstructured":"Kumar, C. S., Narasu, M. L. & Singh, C. R. Pharmacokinetic analysis and structural optimization of inophyllamine-I to forecast as a possible drug candidate. Phytomed. Plus 3, 100422 (2023).","journal-title":"Phytomed. Plus"},{"key":"91568_CR51","doi-asserted-by":"publisher","first-page":"W469","DOI":"10.1093\/nar\/gkae254","volume":"52","author":"Y Myung","year":"2024","unstructured":"Myung, Y., de S\u00e1, A. G. C. & Ascher, D. B. Deep-PK: Deep learning for small molecule pharmacokinetic and toxicity prediction. Nucleic Acids Res. 52, W469\u2013W475 (2024).","journal-title":"Nucleic Acids Res."},{"key":"91568_CR52","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41586-020-2175-2","volume":"582","author":"Y Saito","year":"2020","unstructured":"Saito, Y. et al. Landscape and function of multiple mutations within individual oncogenes. Nature 582, 95\u201399 (2020).","journal-title":"Nature"},{"key":"91568_CR53","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13014-019-1345-6","volume":"14","author":"M Orth","year":"2019","unstructured":"Orth, M. et al. Pancreatic ductal adenocarcinoma: Biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat. Oncol. 14, 141 (2019).","journal-title":"Radiat. Oncol."},{"key":"91568_CR54","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4251\/wjgo.v12.i2.173","volume":"12","author":"P Sarantis","year":"2020","unstructured":"Sarantis, P., Koustas, E., Papadimitropoulou, A., Papavassiliou, A. G. & Karamouzis, M. V. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. World J. Gastrointest. Oncol. 12, 173 (2020).","journal-title":"World J. Gastrointest. Oncol."},{"key":"91568_CR55","doi-asserted-by":"publisher","first-page":"111","DOI":"10.7150\/ijbs.23230","volume":"14","author":"M Zhao","year":"2018","unstructured":"Zhao, M., Mishra, L. & Deng, C. X. The role of TGF-\u03b2\/SMAD4 signaling in cancer. Int. J. Biol. Sci. 14, 111 (2018).","journal-title":"Int. J. Biol. Sci."},{"key":"91568_CR56","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3390\/encyclopedia2030106","volume":"2","author":"S Sch\u00f6niger","year":"2022","unstructured":"Sch\u00f6niger, S. & R\u00fcschoff, J. Mismatch repair deficiency and microsatellite instability. Encyclopedia 2, 1559\u20131576 (2022).","journal-title":"Encyclopedia"},{"key":"91568_CR57","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ccr.2005.01.029","volume":"7","author":"A Gonz\u00e1lez-Garc\u00eda","year":"2005","unstructured":"Gonz\u00e1lez-Garc\u00eda, A. et al. RalGDS is required for tumor formation in a model of skin carcinogenesis. Cancer Cell. 7, 219\u2013226 (2005).","journal-title":"Cancer Cell."},{"key":"91568_CR58","unstructured":"Hanspers, K., Willighagen, E., Tan, A., Ehrhart, F. & Weitz, E. Chromosomal and microsatellite instability in colorectal cancer. Preprint at (2024). https:\/\/www.wikipathways.org\/instance\/WP4216"},{"key":"91568_CR59","unstructured":"Xie, Y. Z. et al. Pancreatic adenocarcinoma pathway. Front. Immunol. 12 (2024)."},{"key":"91568_CR60","doi-asserted-by":"crossref","unstructured":"Chan, D. K. H. & Buczacki, S. J. A. Tumour heterogeneity and evolutionary dynamics in colorectal cancer. Oncogenesis 10, 1\u20139 (2021).","DOI":"10.1038\/s41389-021-00342-x"},{"key":"91568_CR61","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.3390\/cancers12123829","volume":"12","author":"A Aitchison","year":"2020","unstructured":"Aitchison, A. et al. APC mutations are not confined to hotspot regions in early-onset colorectal cancer. Cancers (Basel) 12, 3829 (2020).","journal-title":"Cancers (Basel)"},{"key":"91568_CR62","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3390\/cancers16020412","volume":"16","author":"N Saoudi Gonz\u00e1lez","year":"2024","unstructured":"Saoudi Gonz\u00e1lez, N. et al. Cetuximab as a key partner in personalized targeted therapy for metastatic colorectal cancer. Cancers (Basel). 16, 412 (2024).","journal-title":"Cancers (Basel)"},{"key":"91568_CR63","doi-asserted-by":"crossref","unstructured":"Jin, K., Qian, C., Lin, J. & Liu, B. Cyclooxygenase-2-prostaglandin E2 pathway: A key player in tumor-associated immune cells. Front. Oncol. 13 (2023).","DOI":"10.3389\/fonc.2023.1099811"},{"key":"91568_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12859-019-3008-x","volume":"20","author":"A S\u00e1nchez-Pla","year":"2019","unstructured":"S\u00e1nchez-Pla, A., Salicr\u00fa, M. & Oca\u00f1a, J. An equivalence approach to the integrative analysis of feature lists. BMC Bioinform. 20, 1\u201313 (2019).","journal-title":"BMC Bioinform."},{"key":"91568_CR65","doi-asserted-by":"crossref","unstructured":"Zhang, P. et al. Network pharmacology: Towards the artificial intelligence-based precision traditional Chinese medicine. Brief. Bioinform. 25 (2023).","DOI":"10.1093\/bib\/bbad518"},{"key":"91568_CR66","unstructured":"Shen, L. GeneOverlap: An R package to test and vi-sualize gene overlaps (2023)."},{"key":"91568_CR67","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.3390\/cells11142183","volume":"11","author":"A Ferreira","year":"2022","unstructured":"Ferreira, A. et al. Crucial role of oncogenic KRAS mutations in apoptosis and autophagy regulation: Therapeutic implications. Cells 11, 2183 (2022).","journal-title":"Cells"},{"key":"91568_CR68","doi-asserted-by":"publisher","first-page":"100662","DOI":"10.1016\/j.drup.2019.100662","volume":"48","author":"A Tolios","year":"2020","unstructured":"Tolios, A. et al. Computational approaches in cancer multidrug resistance research: Identification of potential biomarkers, drug targets and drug-target interactions. Drug Resist. Updates 48, 100662 (2020).","journal-title":"Drug Resist. Updates"},{"key":"91568_CR69","doi-asserted-by":"publisher","first-page":"105752","DOI":"10.1016\/j.phrs.2021.105752","volume":"173","author":"W Zhou","year":"2021","unstructured":"Zhou, W. et al. FordNet: recommending traditional Chinese medicine formula via deep neural network integrating phenotype and molecule. Pharmacol. Res. 173, 105752 (2021).","journal-title":"Pharmacol. Res."},{"key":"91568_CR70","doi-asserted-by":"publisher","unstructured":"Wang, F. et al. A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer. Drug Resist. Updates 101077 https:\/\/doi.org\/10.1016\/j.drup.2024.101077 (2024).","DOI":"10.1016\/j.drup.2024.101077"},{"key":"91568_CR71","doi-asserted-by":"publisher","first-page":"e24551","DOI":"10.1016\/j.heliyon.2024.e24551","volume":"10","author":"S El Rhabori","year":"2024","unstructured":"El Rhabori, S. et al. Design of new molecules against cervical cancer using DFT, theoretical spectroscopy, 2D\/3D-QSAR, molecular docking, pharmacophore and ADMET investigations. Heliyon 10, e24551 (2024).","journal-title":"Heliyon"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91568-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91568-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91568-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T21:36:43Z","timestamp":1743457003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91568-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,29]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["91568"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-91568-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,29]]},"assertion":[{"value":"13 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10938"}}